Cerevast Therapeutics

OverviewSuggest Edit

Cerevast Therapeutics, Inc. is a medical technology company with primary emphasis in the field of SonoLysis for the treatment acute ischemic stroke and other vascular disorders. This non-invasive treatment is administered with Cerevast’s proprietary ultrasonic headframe called the ClotBust-ERTM, an operator independent device that can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy for SonoLysis therapy.

Cerevast was formed in September of 2009 following the acquisition of substantially all of the assets of ImaRx Therapeutics, Inc. – a publicly traded company focused on the development of microsphere contrast agents and therapeutics. Through this acquisition, Cerevast gained title to the dominant intellectual property estate and an extensive data package of pre-clinical and clinical studies.

Cerevast has assembled a management team with extensive technical, scientific, commercial and regulatory expertise. The company has also assembled a Scientific Advisory Board comprised of globally recognized clinicians, all of whom are leading experts in the field of SonoLysis, ultrasound development and stroke treatment.

The company’s headquarters are located in Redmond, Washington.

HQBothell, WA, US

Recent NewsAll News

Latest Updates

Employees (est.) (Apr 2021)6
Cybersecurity ratingAMore

Key People/Management at Cerevast Therapeutics

Bradford A. Zakes

Bradford A. Zakes

President & Chief Executive Officer, Chairman
Travis Rothlisberger

Travis Rothlisberger

Vice President of Device Development
Andrew Leo

Andrew Leo

Vice President of Quality and Regulatory Affairs
Kendall Stever

Kendall Stever

Chief Financial Officer
Francesco P. Curra

Francesco P. Curra

Chief Technology Officer
Show more

Cerevast Therapeutics Office Locations

Cerevast Therapeutics has an office in Bothell
Bothell, WA, US (HQ)
12100 NE 195th St #150
Show all (1)

Cerevast Therapeutics Financials and Metrics

Summary Metrics

Founding Date


Cerevast Therapeutics total Funding

$22.4 m

Cerevast Therapeutics latest funding size

$11.4 m

Time since last funding

6 years ago

Cerevast Therapeutics investors

Cerevast Therapeutics's latest funding round in March 2015 was reported to be $11.4 m. In total, Cerevast Therapeutics has raised $22.4 m
Show all financial metrics

Cerevast Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Cerevast Therapeutics Online and Social Media Presence

Embed Graph

Cerevast Therapeutics Blogs

Analysis of Equipoise Shift in CLOTBUST-ER Has Been Published

The results of the CLOTBUST-ER trial, the first phase 3 trial to assess the safety and efficacy of sonothrombolysis, have been published in the April 2019 edition of Lancet Neurology.

Cerevast Therapeutics Frequently Asked Questions

  • When was Cerevast Therapeutics founded?

    Cerevast Therapeutics was founded in 2015.

  • Who are Cerevast Therapeutics key executives?

    Cerevast Therapeutics's key executives are Bradford A. Zakes, Travis Rothlisberger and Andrew Leo.

  • How many employees does Cerevast Therapeutics have?

    Cerevast Therapeutics has 6 employees.

  • Who are Cerevast Therapeutics competitors?

    Competitors of Cerevast Therapeutics include Permobil, RespirTech and Medinol.

  • Where is Cerevast Therapeutics headquarters?

    Cerevast Therapeutics headquarters is located at 12100 NE 195th St #150, Bothell.

  • Where are Cerevast Therapeutics offices?

    Cerevast Therapeutics has an office in Bothell.

  • How many offices does Cerevast Therapeutics have?

    Cerevast Therapeutics has 1 office.